Article Information
History
- January 20, 2021.
Article Versions
- You are currently viewing Version 1 of this article (January 20, 2021 - 10:01).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Renu Verma1,
- Sunita Patil1,
- Nan Zhang2,
- Flora Martinez Figueira Moreira3,
- Marize Teixeira Vitorio3,
- Andrea da Silva Santos3,
- Ellen Wallace4,
- Devasena Gnanashanmugam4,
- David Persing4,
- Rada Savic2,
- Julio Croda5,6 and
- Jason R. Andrews1,*
- 1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
- 2Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
- 3Federal University of Grande Dourados, Dourados, Brazil
- 4Cepheid Inc., Sunnyvale, California, USA
- 5Postgraduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Mato Grosso do Sul, Brazil
- 6Oswaldo Cruz Foundation Mato Grosso do Sul, Mato Grosso do Sul, Brazil
- ↵*Correspondence
Jason Andrews, MD, Division of Infectious Diseases and Geographic Medicine, Biomedical Innovations Building, Room 3458, Stanford University School of Medicine, Stanford, CA 94305, Email: jandr{at}stanford.edu, Phone: +1 650 497 2679
Posted January 20, 2021.
A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment
